273 related articles for article (PubMed ID: 22246902)
21. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
Horning AM; Awe JA; Wang CM; Liu J; Lai Z; Wang VY; Jadhav RR; Louie AD; Lin CL; Kroczak T; Chen Y; Jin VX; Abboud-Werner SL; Leach RJ; Hernandez J; Thompson IM; Saranchuk J; Drachenberg D; Chen CL; Mai S; Huang TH
Prostate; 2015 Nov; 75(15):1790-801. PubMed ID: 26332453
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma.
Dansranjavin T; Wagenlehner F; Gattenloehner S; Steger K; Weidner W; Dammann R; Schagdarsurengin U
Prostate; 2012 Oct; 72(14):1550-8. PubMed ID: 22415519
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
24. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer.
Khor TO; Fuentes F; Shu L; Paredes-Gonzalez X; Yang AY; Liu Y; Smiraglia DJ; Yegnasubramanian S; Nelson WG; Kong AN
Cancer Prev Res (Phila); 2014 Dec; 7(12):1186-97. PubMed ID: 25266896
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.
Bastian PJ; Ellinger J; Heukamp LC; Kahl P; Müller SC; von Rücker A
Eur Urol; 2007 Mar; 51(3):665-74; discussion 674. PubMed ID: 16956712
[TBL] [Abstract][Full Text] [Related]
27. Hypermethylation of CpG islands in primary and metastatic human prostate cancer.
Yegnasubramanian S; Kowalski J; Gonzalgo ML; Zahurak M; Piantadosi S; Walsh PC; Bova GS; De Marzo AM; Isaacs WB; Nelson WG
Cancer Res; 2004 Mar; 64(6):1975-86. PubMed ID: 15026333
[TBL] [Abstract][Full Text] [Related]
28. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
Shiina H; Breault JE; Basset WW; Enokida H; Urakami S; Li LC; Okino ST; Deguchi M; Kaneuchi M; Terashima M; Yoneda T; Shigeno K; Carroll PR; Igawa M; Dahiya R
Cancer Res; 2005 Mar; 65(6):2130-8. PubMed ID: 15781623
[TBL] [Abstract][Full Text] [Related]
29. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
[TBL] [Abstract][Full Text] [Related]
30. Regulation of the ITGA2 gene by epigenetic mechanisms in prostate cancer.
Chin SP; Marthick JR; West AC; Short AK; Chuckowree J; Polanowski AM; Thomson RJ; Holloway AF; Dickinson JL
Prostate; 2015 May; 75(7):723-34. PubMed ID: 25662931
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of d-glucuronyl C5-epimerase expression and epigenetic regulation in prostate cancer.
Prudnikova TY; Soulitzis N; Kutsenko OS; Mostovich LA; Haraldson K; Ernberg I; Kashuba VI; Spandidos DA; Zabarovsky ER; Grigorieva EV
Cancer Med; 2013 Oct; 2(5):654-61. PubMed ID: 24403231
[TBL] [Abstract][Full Text] [Related]
32. Bisulfite methylation analysis of tumor suppressor genes in prostate cancer from fresh and archival tissue samples.
Clark SJ; Millar DS; Molloy P
Methods Mol Med; 2003; 81():219-40. PubMed ID: 12725123
[No Abstract] [Full Text] [Related]
33. Methylation of the CD44 metastasis suppressor gene in human prostate cancer.
Lou W; Krill D; Dhir R; Becich MJ; Dong JT; Frierson HF; Isaacs WB; Isaacs JT; Gao AC
Cancer Res; 1999 May; 59(10):2329-31. PubMed ID: 10344738
[TBL] [Abstract][Full Text] [Related]
34. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
35. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
36. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
[TBL] [Abstract][Full Text] [Related]
37. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
[TBL] [Abstract][Full Text] [Related]
38. A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia.
Basu S; Majumder S; Bhowal A; Ghosh A; Naskar S; Nandy S; Mukherjee S; Sinha RK; Basu K; Karmakar D; Banerjee S; Sengupta S
PLoS One; 2015; 10(5):e0125560. PubMed ID: 25938433
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
Tassidis H; Brokken LJ; Jirström K; Ehrnström R; Pontén F; Ulmert D; Bjartell A; Härkönen P; Wingren AG
Int J Cancer; 2010 May; 126(10):2296-307. PubMed ID: 19795453
[TBL] [Abstract][Full Text] [Related]
40. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer.
Vanaja DK; Ehrich M; Van den Boom D; Cheville JC; Karnes RJ; Tindall DJ; Cantor CR; Young CY
Cancer Invest; 2009 Jun; 27(5):549-60. PubMed ID: 19229700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]